BEDFORD, Mass., November 2, 2017 – First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAIs) announced today two new additions to the First Light team.
William Moffitt joins the First Light Diagnostics board of directors as its chairman. Mr. Moffitt has held executive positions at Baxter Healthcare Corporation and American Hospital Supply. He has also led the point-of-care company I-Stat Corporation from its early research phase through commercialization and IPO to a premium acquisition by Abbott Labs in 2003. He subsequently took the clinical microbiology company Nanosphere through the development stage and IPO to sales.
Geoffrey A. McKinley joins the First Light Diagnostics team as Chief Product Development officer. Prior to First Light, Mr. McKinley held a management role at OpGen, Inc. where he was responsible for the IVD instrument and assay development project. Some of his accomplishments included restructuring resources and re-engineering the quality system to meet FDA 21 CFR 820 (QSR) and ISO 13485 requirements. Prior strategic roles include AdvanDx4, GenturaDx, Osmetech plc, as well as various positions with bioMérieux, Inc. and Analytab Products, Inc. He is an author on 13 U.S. patents and received his Ph.D. in Microbiology from Colorado State University.
“We are at an exciting point in the evolution of our company,” said Don Straus, CEO and founder of First Light Diagnostics. “The addition of experienced executives such as Bill and Geoff to key positions on our team will guide our development and delivery of our breakthrough technology.“
About First Light Diagnostics
First Light Diagnostics is developing and preparing to commercialize, innovative diagnostic products for rapid, sensitive and cost-saving detection of life-threatening infections, and combating the spread of antibiotic resistance. Don Straus is the company’s Founder and primary inventor of the company’s core scientific technology. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the clinical performance of the most advanced commercial laboratory tests with speed, cost-effectiveness, and ease-of-use. The tests rapidly detect infections, identify infectious agents, and determine effective targeted antibiotic therapy. This will improve patient outcomes, reduce healthcare costs, and prevent inappropriate use of powerful antibiotics. To learn more, please visit: www.firstlightidx.com